萨瓦拉制药
SVRA
4.45
-0.29
-6.12%
萨瓦拉制药
US · SVRA
#3247 按市值排名
4.45
-0.29
-6.12%
实时 - 追踪5344个代码 - 心跳于146秒前
· 2026-10-16 20:01
✦ 量化股权信号 计算方式说明
涨跌不一/平稳
- 最近一期（2026/Q3）披露持股的机构数量减少了1家。
- 机构持股总比例基本持平。
机构持股
- 机构持股比例
- 85.95% -0.06pp
- 机构数量
- 203 -1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
VC/PE Fund33.88%
Mutual Fund26.91%
Hedge Fund23.65%
Individual/Insider2.10%
Public Company0.78%
Private Company0.41%
Government Pension Fund0.14%
Insurance Company0.12%
Other11.95%
主要股东 截至 2026-06-30
New Enterprise Associates, Inc.
9.63% · 24.47M 股
Bain Capital Life Sciences Investors, LLC
6.93% · 17.60M 股
VR Management, LLC
5.80% · 14.75M 股
Deerfield Management Company, L.P.
5.34% · 13.57M 股
BlackRock
4.92% · 12.49M 股
TCG Crossover Management, LLC
4.86% · 12.36M 股
Frazier Life Sciences Management, LP
3.83% · 9.72M 股
Polar Capital Holdings Plc
3.75% · 9.54M 股
Vanguard Capital Management, LLC
3.53% · 8.97M 股
Nantahala Capital Management, LLC
2.75% · 6.98M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 23次买入 · 23次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| David Ramsay | Independent Director | 0.98% |
| Matthew Pauls | Chairperson & CEO | 0.31% |
| Kate McCabe | General Counsel | 0.20% |
| David Lowrance | CFO, Chief Administrative Officer & Secretary | 0.17% |
| Anne Erickson | Chief Business Officer | 0.11% |
| Joseph S. McCracken | Lead Independent Director | 0.10% |
| Robert Lutz | Chief Operating Officer | 0.08% |
| Richard Hawkins | Independent Director | 0.05% |
| Nevan Elam | Independent Director | 0.03% |
| An van Es-Johansson | Independent Director | 0.02% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-23 | Braden Parker | Chief Commercial Officer | Sale to Issuer | -29,323 | $5.07 |
| 2026-07-14 | Robert Lutz | Chief Operating Officer | Other Acquisition | +35,000 | -- |
| 2026-07-14 | Robert Lutz | Chief Operating Officer | Other Derivative Acquisition | +70,000 | $5.81 |
| 2026-06-21 | David Lowrance | CFO, Chief Administrative Officer & Secretary | Derivative Exercise and Sale | -580,187 | $1.11–5.68 |
| 2026-03-17 | David Lowrance | CFO, Chief Administrative Officer & Secretary | Derivative Exercise and Sale | -116,760 | $1.11–5.04 |
| 2026-03-17 | David Lowrance | CFO, Chief Administrative Officer & Secretary | Derivative Exercise and Retained | +249,987 | $1.11–4.45 |
| 2026-02-15 | Joseph S. McCracken | Lead Independent Director | Derivative Exercise and Retained | +1,807 | $1.76 |
| 2025-12-18 | David Ramsay | Independent Director | Open Market Disposition | -20,000 | $6.06 |
| 2025-12-17 | David Ramsay | Independent Director | Intent to Sell (Form 144) | -20,000 | $6.11 |
| 2025-12-15 | David Lowrance | CFO, Chief Administrative Officer & Secretary | Other Disposition | -32,000 | -- |
| 2025-12-15 | Matthew Pauls | Chairperson & CEO | Other Disposition | -128,995 | -- |
| 2025-12-13 | David Lowrance | CFO, Chief Administrative Officer & Secretary | Sale to Issuer | -62,960 | $6.92 |
| 2025-12-13 | Matthew Pauls | Chairperson & CEO | Sale to Issuer | -195,705 | $6.92 |
| 2025-12-13 | Robert Lutz | Chief Operating Officer | Sale to Issuer | -67,760 | $6.92 |
| 2025-12-13 | Anne Erickson | Chief Business Officer | Sale to Issuer | -62,960 | $6.92 |
| 2025-12-13 | Kate McCabe | General Counsel | Sale to Issuer | -39,350 | $6.92 |
| 2025-12-09 | Matthew Pauls | Chairperson & CEO | Other Disposition | -23,629 | -- |
| 2025-12-08 | David Ramsay | Independent Director | Other Acquisition | +40,000 | -- |
| 2025-12-08 | Joseph S. McCracken | Lead Independent Director | Other Acquisition | +40,000 | -- |
| 2025-12-08 | Richard Hawkins | Independent Director | Other Acquisition | +40,000 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 20:01:08 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
萨瓦拉制药 讨论区 0 条评论